Issue 45, 2023

Total synthesis of (S)-forphenicinol via asymmetric organocatalysis

Abstract

Practical asymmetric synthesis of (S)-forphenicinol, the active ingredient of immunomodulator and anticancer drug Forfenimex®, from commercially available 2-hydroxy-dimethylterephthalate has been developed. Key steps of the synthesis are a stereogenic-center-forming enantioselective organocatalytic Mannich reaction of protected arylcarbaldimine with a kojic acid derivative and oxidative transformation of the γ-pyrone fragment into the carboxylic group. The total yield of (S)-forphenicinol hydrochloride (99% ee) via the proposed nine-step synthetic scheme (17%) is significantly higher than those attained by known methods (4.6% and 0.8%).

Graphical abstract: Total synthesis of (S)-forphenicinol via asymmetric organocatalysis

Supplementary files

Article information

Article type
Paper
Submitted
27 Sep 2023
Accepted
26 Oct 2023
First published
27 Oct 2023

New J. Chem., 2023,47, 20814-20817

Total synthesis of (S)-forphenicinol via asymmetric organocatalysis

R. A. Kovalevsky, A. S. Kucherenko and S. G. Zlotin, New J. Chem., 2023, 47, 20814 DOI: 10.1039/D3NJ04527G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements